Press Releases

<<  Back

  View printer-friendly version

Aimmune Therapeutics to Host Investor Symposium Featuring Leading Experts in Peanut Allergy

BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 21, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today announced that it will host an Investor Symposium in New York City on December 1, 2016. The event will bring together leading experts to discuss the emerging treatment landscape in peanut allergy. Topics will include a historical overview of immunotherapy approaches, considerations for developing regulated treatment options, Phase 2 data and experience with AR101, and treatment expectations in the peanut-allergic community. The Aimmune management team will also provide a corporate and clinical update and review upcoming milestones. A question and answer session will follow the formal presentations. AR101 is Aimmune’s investigational oral biologic desensitization therapy for peanut allergy, which is currently in Phase 3 clinical development.

Guest Physician Presenters

George Du Toit, MD, is lead author of the LEAP and LEAP-On hallmark studies that showed feeding peanuts to young children can sharply reduce the risk of their developing peanut allergies. Dr. Du Toit is currently an Honorary Senior Lecturer at King's College London and a Pediatric Allergy Consultant in London at Guy's and St. Thomas' NHS Foundation Trust, which is home to one of Europe's largest specialist children's allergy centers. He is also Chair of the Pediatric Section of the European Academy of Allergy and Clinical Immunology (EAACI). His research interests concern the prevention of food allergy, urticarial disorders, exercise and allergy, and allergy to medications in childhood.

Stanley M. Fineman, MD, MBA, has been in private allergy practice for 35 years and is currently a physician at Atlanta Allergy & Asthma. He earned his medical degree from Emory University School of Medicine and completed his internship and residency in Pediatrics at the University of Cincinnati, followed by an Allergy and Immunology fellowship at Harvard University School of Medicine. Dr. Fineman is a past president of the American College of Allergy, Asthma and Immunology and the American Academy of Pediatrics.

Edwin Kim, MD, is Assistant Professor of Medicine and Pediatrics at the University of North Carolina (UNC) School of Medicine. Dr. Kim is also the Director of the UNC Food Allergy Initiative and the director of the UNC allergy and immunology fellowship training program. Dr. Kim gained significant research experience in food allergy while training at Duke and UNC under Dr. Wesley Burks. He earned his MD at Rutgers Robert Wood Johnson Medical School. Dr. Kim also earned an MS in Health Policy and Management from the Harvard School of Public Health and a BS in Biology from the Massachusetts Institute of Technology.

Event and Webcast Details

The Investor Symposium will be held on Thursday, December 1, 2016, from 8:00-10:30 a.m. Eastern Time in New York City. Analysts and investors may register for the event by contacting LifeSci Advisors, LLC, at mac@lifesciadvisors.com. A live webcast of the event may be accessed in the Investor Relations section of Aimmune’s website at www.aimmune.com under the Events page. A replay will be available for at least 30 days.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4-17 years of age and is currently being evaluated in Phase 3 clinical trials in ages 4-55. AR101 is a characterized, regulated, oral biological drug product containing the protein profile found in peanuts. For more information, please see www.aimmune.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Aimmune’s expectations regarding the potential benefits of AR101; and Aimmune’s expectations regarding potential applications of the CODIT™ approach to treating life-threatening food allergies. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the possibility that Aimmune’s clinical trials will not be successful; Aimmune’s dependence on the success of AR101; the company’s reliance on third parties for the manufacture of the company’s product candidates; possible regulatory developments in the United States and foreign countries; and the company’s ability to attract and retain senior management personnel. These and other risks and uncertainties are described more fully in Aimmune's most recent filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended 2015 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2016. All forward-looking statements contained in this press release speak only as of the date on which they were made. Aimmune undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

This press release concerns a product that is under clinical investigation and that has not yet been approved for marketing by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). It is currently limited to investigational use, and no representation is made as to its safety or effectiveness for the purposes for which it is being investigated.

Source: Aimmune Therapeutics, Inc.

Aimmune Therapeutics, Inc.
Investors
Laura Hansen, Ph.D., 650-396-3814
lhansen@aimmune.com
or
Media
Stephanie Yao, 650-351-6479
syao@aimmune.com